Replies to post #117063 on Biotech Values

[iwfal]

that it is likely they bring something else to market, and if they do it is likely another multi-bagger.

As you know, but I have not stated succintly on the board, I guess differently. If they announce only one 'new' thing in, say, a 1 year period then I think the price might pop - say to 30. But then they get taken out at below any reasonable valuation of their market cap. Might be for a nice premium to 30, might even just barely make it to "multibagger" - but might not. But certainly no Dendreon. OTOH if they can pull off 2 or 3 no-overhang announcements (e.g. launch of Copaxone without litigation risk, deal in their unique form of LMWH, and partnership for generic biologics while FDA clarifies that there is a substitution pathway for biologics) then I think they are likely to get to a reasonable recognition of their value. Might still get taken out - but at least at a reasonable value.